Jun Health is the world’s leading single-cell tumor diagnostic company and the first to verify that the Nobel-Prize-winning Warburg effect was applicable to body fluid samples. It created the original single-cell clinical detection platform HK2-seq, with “glucose metabolism markers + single-cell sequencing “technology and published papers in first – class journals such as PNAS, Nature Communications, Analytical Chemistry and Clinical Chemistry. Jun Health researched and developed product lines for the detection of rare tumor cells in urine , serous effusion, blood, and other samples. Much of the equipment and kits are approved by National Medical Products Administration of China. Currently , the product is used in clinical application and research cooperation with Fudan Cancer Hospital, Beijing Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Huashan Hospital, Zhejiang Provincial People’s Hospital, Zhejiang Cancer Hospital, and the First Affiliated Hospital of Suzhou University. The non – invasive testing kit, Uro™, was awarded the highest honor at the college – level by China International Industry Fair in 2020, and was given the Most Industrial Valuable Award at the Revolutionary Cancer Treatment Technology Conference hosted by CSCO.
